1 291

Cited 21 times in

Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer

Authors
 Hee Man Kim  ;  Seungmin Bang  ;  Jeong Youp Park  ;  Jinsil Seong  ;  Si Young Song  ;  Jae Bock Chung  ;  Seung Woo Park 
Citation
 CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.63(3) : 535-541, 2009 
Journal Title
 CANCER CHEMOTHERAPY AND PHARMACOLOGY 
ISSN
 0344-5704 
Issue Date
2009
MeSH
Adult ; Aged ; Aged, 80 and over ; Combined Modality Therapy ; Disease Progression ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Oxonic Acid/therapeutic use* ; Pancreatic Neoplasms/drug therapy* ; Pancreatic Neoplasms/radiotherapy* ; Survival Rate ; Tegafur/therapeutic use* ; Treatment Outcome
Keywords
S-1 ; Pancreatic cancer ; Locally advanced ; Concurrent chemoradiotherapy
Abstract
PURPOSE: S-1 has a favorable effect in unresectable pancreatic cancer and a potential radiosensitizer. In addition, daily oral administration of S-1 is more convenient than continuous infusion of 5-fluorouracil. This study was designed to evaluate the efficacy and safety of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. METHODS: Eligibility criteria were histologically proven pancreatic adenocarcinoma, locally advanced disease, and no previous treatment. S-1 was administered orally at a dose of 40 mg/m(2) twice daily from day 1 to 14 and from day 22 to 35, and concurrent radiotherapy (a total dose of 50.4 Gy) was delivered in 28 fractions. One month after treatment completion, tumor response was evaluated by computed tomography (CT). RESULTS: A total of 25 patients were evaluable for efficacy and toxicity on the basis of the intention-to-treat analysis. The response rate and disease control rate were 24.0 and 68.0%, respectively. There was no treatment-related death or grade 4 toxicity. The most common grade 3 hematologic and non-hematologic toxicities were thrombocytopenia (4.0%) and anorexia (20%), respectively. All toxicities were tolerable and transient. The median time-to-progression and median overall survival were 6.5 months (95% confidence interval, 4.1-9.0 months) and 12.9 months (95% confidence interval, 6.7-19.0 months), respectively, and the 1-year survival rate was estimated to be 43%. CONCLUSIONS: S-1 and concurrent radiotherapy shows favorable efficacy for disease control against locally advanced pancreatic cancer and was well tolerated with no severe toxicities.
Full Text
http://link.springer.com/article/10.1007%2Fs00280-008-0836-1
DOI
10.1007/s00280-008-0836-1
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hee Man(김희만)
Park, Seung Woo(박승우) ORCID logo https://orcid.org/0000-0001-8230-964X
Park, Jeong Youp(박정엽) ORCID logo https://orcid.org/0000-0003-0110-8606
Bang, Seungmin(방승민) ORCID logo https://orcid.org/0000-0001-5209-8351
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
Song, Si Young(송시영) ORCID logo https://orcid.org/0000-0002-1417-4314
Chung, Jae Bock(정재복)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/103352
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse